Abstract:BACKGROUND/AIMS:Minimal residual leukemia cells (MRLs) are difficult to eradicate through traditional treatment and therefore remain to be a major threat to the long-term survival of leukemia patients. Tumor-derived exosomes (TEXs), which carry tumor associated antigens (TAA), may be a potential cell-free tumor vaccine for the specific eradication of MRLs. However, TEXs are intended to be less immunogenic due to exosomal TGF-β1. To further optimize the efficacy of TEX-based vaccines, we investigated whether exosomes from TGF-β1 silenced leukemia cells (LEXTGF-β1si) had an increased potential to induce a specific antitumor effect compared with non-modified exosomes.METHODS:Exosomal TGF-β1 was downregulated via lentiviral shRNA silencing of TGF-β1 in leukemia cells. The characteristics of LEXTGF-β1si were determined via electron microscopy, western blot analysis, and flow cytometry. The antitumor effect of LEXTGF-β1si was evaluated by detecting the properties of LEXTGF-β1si-pulsed dendritic cells (DCs), CD4+ T-cell proliferation, Th1 cytokine secretion, specific CTL activity, and NK cell function. Moreover, to verify the superiority of LEXTGF-β1si immunization, LEXTGF-β1si was subcutaneously injected into DBA/2 mice: either followed by tumor challenge or tumor bearing.RESULTS:The lentiviral shRNA silencing of TGF-β1 in parental leukemia cells successfully downregulated the TGF-β1 level in leukemia cell derived exosomes (LEX). LEXTGF-β1si was uptaken by DCs and was more potent in promoting DC function by upregulating the surface expression of costimulatory factors and MHC class II molecules, while inducing the secretion of IL-12p70 and TNF-α. Furthermore, immunization with LEXTGF-β1si facilitated CD4+ T-cell proliferation and Th1 cytokine secretion, and stimulated stronger specific cytotoxic lymphocyte (CTL) response and nature killer (NK) cell cytotoxicity more efficiently compared to non-modified LEX. In mice models, immunization with LEXTGF-β1si resulted in a more potent capability to inhibit tumor growth and to prolong survival, suggesting that LEXTGF-β1si was more effective in both protective and therapeutic antitumor tests than non-modified LEX.CONCLUSIONS:These data suggested that down-regulation of exosomal TGF-β1 effectively induced potent anti-tumor immunity. Our strategy of optimizing exosome vaccine may have promising potential for leukemia immunotherapy.

Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Anti-tumor Effects of Exosomes Derived from Tumor Cells Modified by IFN-γ Gene

In vivo anti-tumor effect of tumor cell-derived exosomes combined with BCG

Tumor Cell-Derived Exosome-Targeted Dendritic Cells Stimulate Stronger CD8+ CTL Responses and Antitumor Immunities

Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.

Enhanced Antitumor Effects of Exosomes Derived from Heat-Shocked E.G7-OVA Tumor Cells

A Novel HER-2-specific Exosome-Targeted T Cell-Based Vaccine: Immunotherapy of Established Lung Metastasis in Transgenic HLA-A2/HER-2 Mice (155.37)

Increasing the Immune Activity of Exosomes: the Effect of Mirna-Depleted Exosome Proteins on Activating Dendritic Cell/cytokine-Induced Killer Cells Against Pancreatic Cancer.

Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.

A study on anti-tumor immunity induced by gene-modified melanoma B16 cells.

Animal Experiments of Immunotherapy with Ovarian Tumor Vaccine During Lymphopenia Induced by Chemotherapy

Exosomal Pmhc-I Complex Targets T Cell-Based Vaccine to Directly Stimulate CTL Responses Leading to Antitumor Immunity in Transgenic FVBneuN and HLA-A2/HER2 Mice and Eradicating Trastuzumab-Resistant Tumor in Athymic Nude Mice

Dendritic Cell-Derived Exosomes Stimulate Stronger Cd8(+) Ctl Responses and Antitumor Immunity Than Tumor Cell-Derived Exosomes

Enhancement of Anti-Leukemia Immunity by Leukemia–Derived Exosomes Via Downregulation of TGF-β1 Expression

Enhanced Immunogenicity of Leukemia-Derived Exosomes Via Transfection with Lentiviral Vectors Encoding Costimulatory Molecules

Exosomes derived from Rab27a‑overexpressing tumor cells elicit efficient induction of antitumor immunity.

Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo

Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor

THE IN VIVO ANTI-TUMOR EFFECTS OF TUMOR VACCINE INDUCED BY ADENOVIRUS-MEDIATED IL-2 GENE THERAPY